Mural Oncology (MURA) Competitors $1.25 +0.07 (+5.93%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. ANNX, ITOS, CDTX, ACB, TSVT, CRDF, OLMA, DRUG, LFCR, and MNPRShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Annexon (ANNX), iTeos Therapeutics (ITOS), Cidara Therapeutics (CDTX), Aurora Cannabis (ACB), 2seventy bio (TSVT), Cardiff Oncology (CRDF), Olema Pharmaceuticals (OLMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Annexon iTeos Therapeutics Cidara Therapeutics Aurora Cannabis 2seventy bio Cardiff Oncology Olema Pharmaceuticals Bright Minds Biosciences Lifecore Biomedical Monopar Therapeutics Annexon (NASDAQ:ANNX) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Which has better earnings & valuation, ANNX or MURA? Annexon is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.02-2.01Mural OncologyN/AN/A-$207.45M-$7.58-0.16 Does the media favor ANNX or MURA? In the previous week, Mural Oncology had 24 more articles in the media than Annexon. MarketBeat recorded 26 mentions for Mural Oncology and 2 mentions for Annexon. Annexon's average media sentiment score of 1.86 beat Mural Oncology's score of -0.29 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mural Oncology 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 6 Very Negative mention(s) Neutral Do analysts rate ANNX or MURA? Annexon presently has a consensus price target of $17.25, indicating a potential upside of 739.42%. Mural Oncology has a consensus price target of $13.00, indicating a potential upside of 978.84%. Given Mural Oncology's higher probable upside, analysts plainly believe Mural Oncology is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, ANNX or MURA? Annexon has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.66, suggesting that its share price is 266% more volatile than the S&P 500. Does the MarketBeat Community favor ANNX or MURA? Annexon received 47 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 77.46% of users gave Annexon an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5577.46% Underperform Votes1622.54% Mural OncologyOutperform Votes880.00% Underperform Votes220.00% Is ANNX or MURA more profitable? Annexon's return on equity of -38.99% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -38.99% -33.90% Mural Oncology N/A -70.10%-61.30% Do institutionals and insiders believe in ANNX or MURA? 80.2% of Mural Oncology shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 0.1% of Mural Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAnnexon beats Mural Oncology on 9 of the 15 factors compared between the two stocks. Remove Ads Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.02M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.137.3523.5018.55Price / SalesN/A208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book0.086.256.814.11Net Income-$207.45M$142.34M$3.20B$247.18M7 Day Performance-68.54%-8.43%-5.42%-4.05%1 Month Performance-67.26%-9.99%-0.12%-6.41%1 Year Performance-75.36%-12.60%7.61%-2.08% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology2.4756 of 5 stars$1.25+5.9%$13.00+940.0%-75.9%$20.85MN/A-0.13119Analyst RevisionANNXAnnexon2.3693 of 5 stars$2.70+12.5%$15.80+485.2%-68.6%$263.30MN/A-2.5760Positive NewsGap DownITOSiTeos Therapeutics2.7174 of 5 stars$6.89+0.1%$25.75+273.7%-53.7%$263.16M$35M-2.1990CDTXCidara Therapeutics4.3554 of 5 stars$23.63+5.2%$39.14+65.6%+21.7%$258.82M$1.28M-0.9390Short Interest ↑ACBAurora Cannabis0.3916 of 5 stars$4.57+2.5%N/A+0.9%$256.14M$320.81M91.421,340News CoverageGap UpTSVT2seventy bio3.0965 of 5 stars$4.96+0.2%$6.67+34.4%-7.5%$255.88M$45.62M-2.67440Earnings ReportShort Interest ↓CRDFCardiff Oncology1.6381 of 5 stars$3.79+1.1%$11.67+207.8%-38.4%$249.47M$683,000.00-4.0320OLMAOlema Pharmaceuticals2.6884 of 5 stars$4.32+2.1%$27.50+536.6%-63.7%$247.53MN/A-1.9770Analyst ForecastGap DownHigh Trading VolumeDRUGBright Minds Biosciences2.7588 of 5 stars$34.80-1.0%$84.33+142.3%+2,941.9%$245.13MN/A-204.69N/APositive NewsLFCRLifecore Biomedical1.3038 of 5 stars$6.60+0.8%$8.00+21.2%+29.0%$244.37M$130.86M-11.79690MNPRMonopar Therapeutics1.164 of 5 stars$37.60-6.0%$44.00+17.0%+1,084.4%$244.10MN/A-19.0910Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Annexon Competitors iTeos Therapeutics Competitors Cidara Therapeutics Competitors Aurora Cannabis Competitors 2seventy bio Competitors Cardiff Oncology Competitors Olema Pharmaceuticals Competitors Bright Minds Biosciences Competitors Lifecore Biomedical Competitors Monopar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MURA Stock Free MURA Stock Alerts